You can just call us +1-678-420-5402

Oncology Market

The Axess Oncology Physician Network features the  C-level owners of 550+ leading community oncology practices – AND the oncology and hematology physician department heads of top U.S. academic cancer centers. 

Learn more about our PRODUCTS Download an informative brochure about Axess

over 900 physicians – more than 6% of all practicing U.S. oncologists

The exclusive Axess Oncology Physician Network provides a direct connection to the mindshare of oncologists and hematologists at the leading edge of clinical practice.  

With dwindling access to key stakeholders, healthcare businesses trust Axess Oncology to open vital knowledge-sharing channels to providers, payers, and patients.Axess Oncology has ready access to the most influential oncologists in the market.

Accessing oncologists is increasingly challenging – and your mission to secure an accurate and actionable picture of physician opinion is difficult to achieve.


 The busiest, most influential oncologists do not participate in traditional market research and have limited time to spend with industry representatives.

We deliver more than robust data – we translate market dynamics into definitive, actionable insights captured directly from prescribers, payers, and patients.  Our business intelligence solutions help our partners ground their strategic and investment decisions in the opinions, practices, and expertise of the most important decision-makers in oncology and hematology.

THE oncologists who drive the market are often the most difficult physicians to accesss to Oncologists is becoming increasingly restricted


of Oncologists significantly restricted access by industry representatives in the past 3 years

of Oncologists have introduced new restrictions for industry representatives since introduction of the Sunshine Act in September, 2013

of Oncologist will reduce their participation in traditional Ad Boards as a result of the ACA/Sunshine Act

of Axess Oncology Physician Network oncologists are self-described as “No See” or “difficult to see”